Medpace slips after bookings decline

Shares of contract research organization Medpace MEDP.O fall 9.4% to $261.76 in extended trading

Co's Q1 new business awards fall 18.8% to $500 mln, with a 0.90x book-to-bill ratio, number of orders received to those fulfilled

Co's Q1 backlog decreases 2.1% to $2.85 bln

However, co reports Q1 sales and EPS above analysts' estimates - LSEG

Co posts Q1 sales of $558.6 mln, above est. of $527.2 mln

Co reports Q1 earnings of $3.67/shr vs. est. of $3.06/shr

As of last close, stock down ~13% YTD